Serine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Serine: Familial visceral myopathy
One-Sentence Summary
Serine is a proteinogenic amino acid, and in Canada it is marketed as a component of parenteral nutrition products. The TxGNN model predicts it may be effective for familial visceral myopathy, but there are 0 clinical trials and 0 publications supporting this prediction. This is a model prediction only, and the data compiled for this report do not support a mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 20 of 20) |
| Number of DINs | 20 (marketed: 20) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, serine is a proteinogenic amino acid that is supplied as a nutritional component in parenteral nutrition amino acid solutions. Its link to the original indications (open-angle glaucoma and pulmonary tuberculosis) does not come from label text, and the source has not been verified.
Familial visceral myopathy is a rare genetic disorder of gut smooth muscle, typically associated with defects in genes such as ACTG2. The data compiled for this report show no mechanistic connection between serine and these defects. The very high TxGNN score (0.9999) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, and the prediction is probably a TxGNN model (deep learning) artifact.
Several other top predictions show the same pattern. Myopathic and unclassified intestinal pseudo-obstruction have identical scores (0.9997). This suggests similarities the TxGNN model (deep learning) learned between related diseases rather than independent evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for familial visceral myopathy.
For context, the second-ranked prediction (intestinal obstruction) and the sixth-ranked prediction (angle-closure glaucoma) returned publications. These appear to be keyword matches only. They concern Peutz-Jeghers syndrome, which is caused by variants in the serine/threonine kinase STK11, and the serine protease PRSS56 in angle-closure glaucoma. None evaluates serine as a therapy.
Canada Market Information
Serine is marketed in Canada through 20 valid licences, mainly parenteral nutrition products. Dosage form and approved indication text are not available in the compiled data. The first five licences are listed below.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00872296 | TRAVASOL | Not available | Not available |
| 02498448 | CLINIMIX | Not available | Not available |
| 02498456 | CLINIMIX | Not available | Not available |
| 02498464 | CLINIMIX | Not available | Not available |
| 02510324 | ESSEPNA | Not available | Not available |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report, and no drug interaction records were found. Please refer to the package insert for safety information.
The knowledge graph does list contraindication links to the following conditions. These come from graph edges, not from label text, and should be verified against the product monograph:
- Renal: kidney disease, chronic kidney disease, chronic renal failure syndrome, end stage renal failure, nephrolithiasis, nephrocalcinosis, acute urate nephropathy
- Metabolic: diabetes mellitus, diabetic ketoacidosis, hypercalcemia, humoral hypercalcemia of malignancy, phosphorus metabolism disease
- Cardiovascular: heart disease, cardiovascular disease, ventricular fibrillation, digitalis poisoning
- Neuropsychiatric: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder, psychotic disorder, schizophreniform disorder, schizoaffective disorder, mental disorder, substance abuse/dependence
- Other: sarcoidosis, vitamin B12 deficiency, megaloblastic anemia
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials or relevant publications, and no plausible mechanism links serine to familial visceral myopathy. The literature found for other predicted indications consists of keyword matches on “serine” rather than evidence of therapeutic benefit.
To proceed, the following is needed:
- Mechanism of action data, and evidence of a biological link between serine and visceral smooth muscle disease
- Preclinical studies (for example, disease models of ACTG2-related myopathy) showing any effect of serine
- Health Canada package insert warnings and contraindications, so that safety screening can begin
- Verification of the original indications (open-angle glaucoma, pulmonary tuberculosis), whose source has not been verified
- Dosage form and approved indication details for the Canadian licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.